United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Progress in the development of a COVID-19 vaccine was all investors need to hear to help propel stocks to hit new heights on Monday. Both the S&P 500 and the Dow Jones industrial average closed sharply higher after Pfizer and BioNTech announced that their COVID-19 vaccine was found to be more than 90% effective in preventing the illness during its phase-three trial, setting it up for an emergency rollout. Both indexes surged to intraday records during the session.

Dow closes 835 points higher after hitting intraday record on Pfizer vaccine enthusiasm

BioNTech SE

Boris Johnson said: “I just don't want to let people run away with the idea that this . . . is necessarily a home run, a slam dunk, a shot to the back of the net yet.

Pfizer vaccine is not a ‘slam dunk,' warns U.K. prime minister

Pfizer and German partner BioNTech have announced a new vaccine that may be effective at preventing COVID-19, but you shouldn't make plans for a big holiday party just yet. In a press release on Monday, the company announced the vaccine is more than 90% effective at preventing COVID-19, according to data from an ongoing trial. This is the first report of positive results from a COVID-19 vaccine trial. 

The Pfizer vaccine will not save Christmas, or even Easter and Passover, experts say

McDonald's

Restaurant Brands

Shake Shack

Pfizer's vaccine data was welcome news for many restaurant stocks.

Why These Fast Food Stocks Popped Monday Morning

A senior administration official said Monday that U.S. health officials are “extremely encouraged” by the announcement that Pfizer's coronavirus vaccine is highly effective in preventing Covid-19.

U.S. health officials 'very optimistic' Pfizer coronavirus vaccine and others 'could effectively end the pandemic'

The vaccine uses a new, innovative form of biotechnology to make the body produce antibodies to protect itself against the virus. In January, as cases of the new, mysterious coronavirus were growing in China—but two months before the World Health Organization declared the disease a pandemic—a handful of small biotech companies began scrambling to develop vaccines using an as-yet-unproven technology platform that relies on something called messenger RNA, usually shortened to mRNA.

How Pfizer's COVID-19 vaccine works: mRNA

Pfizer will likely have millions of coronavirus vaccine doses ready by the end of 2020 — and the company's CEO is willing to be one of the first to take it. The Manhattan-based drugmaker expects to churn out up to 50 million doses of the shot globally this year and is in “a very, very.

Pfizer CEO wants to be ‘among the first' to take COVID-19 vaccine

Boeing

An effective vaccine could start rolling out this year, marking the beginning of the end of the pandemic.

Dow Jones Rockets 1,300 Points on Pfizer Vaccine News; Boeing Stock Soars; McDonald's Stock Drops Despite Earnings Beat

News that Pfizer Inc's experimental COVID-19 vaccine is more than 90% effective based on initial trial results renewed hope on Monday among world leaders, scientists and global investors that the battle against a pandemic that has killed over a million people could be won.

Pfizer COVID-19 vaccine news delivers hope around the globe

Bloomin' Brands

Dine Brands Global

Brinker International

Texas Roadhouse

News that Pfizer has an effective vaccine sent the sector surging.

Why Casual-Dining Stocks Are Soaring Today

This morning, we covered two pharmaceutical stocks that exploded after announcing some more-than-optimistic coronavirus vaccine news.

Options Traders Swarm PFE, BNTX After Vaccine News

Pfizer's encouraging news about the effectiveness of its Covid-19 vaccine came nearly a week after Election Day. But Pfizer CEO Albert Bourla says the timing had nothing to do with politics.

Pfizer CEO: Our vaccine timing had nothing to do with politics

Although the details of interim data from the Phase 3 trials of Pfizer Inc's (NYSE: PFE) COVID-19 vaccine study rea unclear, the results represent “a solid win” for the company, according to BofA Securities. The Pfizer Analyst: Geoff Meacham maintained a Neutral rating on Pfizer with an unchanged $39 price target.

Pfizer Analyst: Coronavirus Vaccine Moving Closer To Emergency Use Authorization

U.S. Health and Human Services Secretary Alex Azar said on Monday it would take several weeks for U.S. regulators to receive and then process data on Pfizer Inc's vaccine for the coronavirus before the government could potentially approve it.

Potential approval of Pfizer vaccine still several weeks away: U.S. official

Pfizer says its experimental coronavirus vaccine more than 90 percent effective in trials

Pfizer Inc. (PFE) shares hit new 52-week high after positive results of Covid-19 vaccine

Israel said it asked the U.S. government on Monday to help it get access to Pfizer's potential COVID-19 vaccine.

Israel asks for U.S. help in getting potential Pfizer COVID-19 vaccine

Pfizer (PFE Quick QuotePFE - Free Report) may have discovered the COVID-19 vaccine that the world has been waiting for since this pandemic began. The equity markets are soaring this morning, being led by the cyclical underperformers, while 2020's parabolic tech stocks take a seat on the sidelines for once.

What A Vaccine Means For The Stock Market

"I had zero worry" going into the trial whether the vaccine was going to be safe, Isaacson told CNBC. But he does not know if he got the vaccine or the placebo.

Walter Isaacson, a participant in Pfizer's Covid vaccine trial, describes what it's like

AstraZeneca

Johnson & Johnson

Moderna

Novavax

A safe and effective Covid-19 vaccine is seen by investors and policymakers as a solution to get the global economy back on track.

Coronavirus vaccine frontrunner Pfizer delivers key trial data – here's where the other vaccines stand

Talk about starting out a new week with a renewed sense of optimism! Market indexes in Monday's pre-market trading are practically off the charts: the Dow +1600 points, the Nasdaq +140 points and the S&P 500 +160.

Positive News on COVID-19 Vaccine

A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.

Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX

On Monday, the German biotech and its partner Pfizer announced that initial data shows their COVID-19 vaccine candidate is more than 90% effective.

Why BioNTech Stock Is Skyrocketing Today After Gaining 23% Last Month

The two companies reported great news for COVID-19 vaccine candidate BNT162b2.

Why Pfizer and BioNTech Stocks Are Soaring Today

The European Union drug regulator said on Monday it had not yet received results from large-scale trials on the COVID vaccines being developed by Pfizer and BioNTech and that it was currently assessing earlier data on the quality of the shot.

EU drug regulator says it is assessing early data from Pfizer COVID vaccine

Shares of both Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

News for Pfizer Stock (PFE)